title: Cancer chemotherapy: a SN-38 (7-ethyl-10-hydroxycamptothecin) glucuronide prodrug for treatment by a PMT (Prodrug MonoTherapy) strategy.
abstract: A glucuronide-based prodrug of SN-38 (7-ethyl-10-hydroxycamptothecin) has been synthesized for use in a Prodrug MonoTherapy Strategy (PMT). Since this prodrug is significantly less cytotoxic than SN-38 itself and efficiently releases the drug in vitro in the presence of beta-D-glucuronidase, it can be considered as an appropriate candidate for cancer treatment by a PMT strategy.
authors.affiliation: UMR176 CNRS/Institut Curie, 26, rue d'Ulm, 75248 Paris Cedex 05, France.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Angenault
authors.forename: Sylvie
authors.initials: S
authors.lastname: Thirot
authors.forename: Frédéric
authors.initials: F
authors.lastname: Schmidt
authors.forename: Claude
authors.initials: C
authors.lastname: Monneret
authors.forename: Bruno
authors.initials: B
authors.lastname: Pfeiffer
authors.forename: Pierre
authors.initials: P
authors.lastname: Renard
mesh_terms: D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology*; D005966:Glucuronidase / Q000378:metabolism; D020719:Glucuronides / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology*; D019073:HT29 Cells; D006801:Humans; D020128:Inhibitory Concentration 50; D000077146:Irinotecan; D011355:Prodrugs / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D020719:Glucuronides; D011355:Prodrugs; D000077146:Irinotecan; D005966:Glucuronidase; D002166:Camptothecin